Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek) for Cystic Fibrosis
March 17, 2025 (Issue: 1724)
The FDA has approved Alyftrek (Vertex), an oral
fixed-dose combination of the cystic fibrosis
transmembrane conductance regulator (CFTR)
modulators vanzacaftor, tezacaftor, and deutivacaftor,
for once-daily treatment of cystic fibrosis (CF)...more
- Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis. Med Lett Drugs Ther 2020; 62:5.
- T Ong and BW Ramsey. Cystic fibrosis: a review. JAMA 2023; 329:1859. doi:10.1001/jama.2023.8120
- H Grasemann and F Ratjen. Cystic fibrosis. N Engl J Med 2023; 389:1693. doi:10.1056/nejmra2216474
- PG Middleton et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019; 381:1809. doi:10.1056/nejmoa1908639
- HGM Heijerman et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019; 394:1940. doi:10.1016/s0140-6736(19)32597-8
- Vertex Pharmaceuticals Press Release. Vertex announces US FDA approval of Alyftrek, a once-daily next-in-class CFTR modulator for the treatment of cystic fibrosis. December 20, 2024. Available at: https://bit.ly/4hS3H6J. Accessed February 27, 2025.
- C Keating et al. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med 2024 Dec 20 (epub). doi:10.1016/s2213-2600(24)00411-9
- JE Hoppe et al. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med 2024 Dec 20 (epub). doi:10.1016/s2213-2600(24)00407-7
- B Collins et al. Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor. J Cyst Fibros 2022; 21:725. doi:10.1016/j.jcf.2021.12.004
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Vanzacaftor, tezacaftor and deutivacaftor. [Updated 2025 Jan 15]. Available at: https://bit.ly/4khjeOO. Accessed February 27, 2025.
- EF Nash et al. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators – an international survey. J Cyst Fibros 2020; 19:521. doi:10.1016/j.jcf.2020.02.018
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
